Borderline personality disorder is pervasive instability of affect, identity, interpersonal relationships, and behavior. The DSM-5 criteria require 5 of 9 features: frantic efforts to avoid abandonment, unstable and intense interpersonal relationships (alternating idealization/devaluation), identity disturbance, impulsivity in potentially self-damaging areas (spending, sex, substance use, binge eating, reckless driving), recurrent self-harm or suicidal behavior, affective instability (intense mood reactivity to environmental cues), chronic emptiness, inappropriate intense anger, transient stress-related paranoid ideation or dissociative symptoms.
The neurobiology: amygdala-PFC dysregulation. Amygdala hyperreactivity to emotional stimuli (particularly faces with neutral or ambiguous expressions, which BPD patients often perceive as threatening). Reduced top-down regulation from prefrontal cortex. Often combined with early developmental trauma producing the attachment patterns and emotion regulation deficits that characterize the disorder.
The clinical reality: patients with BPD often arrive in crisis — emergency department after self-harm, hospitalized after suicide attempt, in psychiatric care after relationship rupture. The presentation can feel overwhelming to clinicians who don't have training in BPD-specific approaches. Countertransference reactions are common; clinicians often feel pulled toward extremes (rescuing or distancing). Recognizing the dynamics is the first step toward effective care.
The diagnostic stigma problem: BPD has historically been one of the more stigmatized diagnoses in psychiatry. Patients are sometimes dismissed as "difficult," "manipulative," "attention-seeking." This framing is harmful and inaccurate — BPD reflects measurable circuit dysregulation and developmental experience, not character defect. The diagnosis should be made openly and discussed with the patient; secret-keeping perpetuates stigma.
Dialectical Behavior Therapy (DBT) — Marsha Linehan's protocol — is the most evidence-based treatment. Multiple RCTs demonstrate substantial effect on self-harm, suicide attempts, hospitalizations, emotion regulation, and treatment retention. Comprehensive DBT includes:
Individual therapy — weekly sessions focused on hierarchy of treatment targets (life-threatening behaviors first, treatment-interfering behaviors next, quality of life behaviors third).
Skills training group — weekly 2-hour groups teaching four modules: mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness.
Phone coaching — brief between-session coaching for skill application in real-life situations.
Therapist consultation team — weekly therapist support, considered essential for therapist sustainability.
Other evidence-based therapies: Mentalization-Based Therapy (Bateman/Fonagy), Transference-Focused Therapy (Kernberg), Schema-Focused Therapy (Young), General Psychiatric Management (Gunderson). All have evidence; DBT has the largest evidence base for self-harm and suicidality specifically.
Pharmacotherapy is adjunctive. No medication has FDA approval for BPD itself. Symptoms-based approach: SSRIs for comorbid mood/anxiety; mood stabilizers (lamotrigine, valproate) for affective lability; atypical antipsychotics at low dose for transient psychotic symptoms or severe agitation. Avoid: benzodiazepines (can produce disinhibition and worsen self-harm), polypharmacy.
Suicide and self-harm management: chronic risk requires different framework than acute risk. Safety planning (Stanley-Brown), means restriction, ongoing DBT engagement, structured response to crises that doesn't reward escalation while remaining humane.
When you encounter a patient with BPD, the framework matters enormously. The diagnosis is real, the disorder is treatable, and the patient deserves the same dignity any other patient deserves. DBT and related evidence-based therapies produce substantial outcomes. The stigma that has historically attached to this diagnosis is itself a barrier to effective care.